NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free RYTM Stock Alerts $43.33 +1.54 (+3.69%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$41.79▼$43.6650-Day Range$39.12▼$52.4452-Week Range$15.50▼$52.57Volume876,116 shsAverage Volume585,071 shsMarket Capitalization$2.61 billionP/E RatioN/ADividend YieldN/APrice Target$47.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Rhythm Pharmaceuticals alerts: Email Address Rhythm Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside9.4% Upside$47.40 Price TargetShort InterestBearish15.30% of Shares Sold ShortDividend StrengthN/ASustainability-1.80Upright™ Environmental ScoreNews Sentiment0.43Based on 11 Articles This WeekInsider TradingSelling Shares$7.61 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.03) to ($1.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.74 out of 5 starsMedical Sector706th out of 939 stocksPharmaceutical Preparations Industry338th out of 444 stocks 1.5 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.40, Rhythm Pharmaceuticals has a forecasted upside of 9.4% from its current price of $43.33.Amount of Analyst CoverageRhythm Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.30% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 2.22%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Rhythm Pharmaceuticals is -1.80. Previous Next 3.0 News and Social Media Coverage News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Rhythm Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest5 people have searched for RYTM on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows8 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,610,988.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Rhythm Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.03) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -13.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -13.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 15.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial Here About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More RYTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RYTM Stock News HeadlinesMarch 28, 2024 | marketbeat.com7 Stocks That Will Drive the Weight Loss Drugs Market (RYTM)The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.March 23, 2024 | insidertrades.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 18,235 Shares of StockMarch 29, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 20, 2024 | insidertrades.comHunter C. Smith Sells 15,515 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockMarch 20, 2024 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CEO Sells $1,784,274.68 in StockMarch 25, 2024 | globenewswire.comRhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific AgonistMarch 24, 2024 | americanbankingnews.comJoseph Shulman Sells 18,235 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockMarch 23, 2024 | msn.comWatch: Singing dog Nova with "voice of an angel" performs Rhythm of the Night at RSPCA Sheffield shelterMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 22, 2024 | yahoo.comBongee Bear and the Kingdom of Rhythm Streaming: Watch & Stream Online via Amazon Prime VideoMarch 22, 2024 | finance.yahoo.comChief Technical Officer Joseph Shulman Sells 18,235 Shares of Rhythm Pharmaceuticals Inc (RYTM)March 22, 2024 | msn.comRhythm City welcomes Banda MagueyMarch 20, 2024 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Yann Mazabraud Sells 16,000 SharesMarch 20, 2024 | finance.yahoo.comInsider Sell: CFO Hunter Smith Sells 15,515 Shares of Rhythm Pharmaceuticals Inc (RYTM)March 20, 2024 | finance.yahoo.comInsider Sell: Chief Technical Officer Joseph Shulman Sells 15,515 Shares of Rhythm ...March 20, 2024 | finance.yahoo.comInsider Sell: Rhythm Pharmaceuticals Inc (RYTM) CEO David Meeker Disposes of 45,494 SharesMarch 19, 2024 | msn.comRhythm City, Davenport, will bloom with Gin Blossoms alt rockMarch 16, 2024 | finance.yahoo.comRYTM Dec 2024 40.000 putMarch 16, 2024 | finance.yahoo.comRYTM Apr 2024 70.000 callMarch 16, 2024 | finance.yahoo.comRYTM Jul 2024 22.500 putMarch 15, 2024 | msn.comRhythm Games With The Most Unique GameplayMarch 14, 2024 | yahoo.comBristol Rhythm AFC looking for sponsorship as inaugural season draws closerMarch 11, 2024 | globenewswire.comRhythm Pharmaceuticals Announces New Employment Inducement GrantsMarch 6, 2024 | globenewswire.comRhythm Pharmaceuticals Announces Participation at Upcoming Investor ConferencesMarch 3, 2024 | finance.yahoo.comRhythm Pharmaceuticals Full Year 2023 Earnings: Revenues DisappointMarch 2, 2024 | msn.comWATCH: ‘Rhythm City’s’ Suffocate ‘new look’ explainedFebruary 28, 2024 | msn.comInteractive Drumming Programs At Soulshine Rhythm ExperienceSee More Headlines Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/29/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RYTM CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees226Year FoundedN/APrice Target and Rating Average Stock Price Target$47.40 High Stock Price Target$55.00 Low Stock Price Target$27.00 Potential Upside/Downside+9.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,680,000.00 Net Margins-238.50% Pretax Margin-237.79% Return on Equity-96.02% Return on Assets-55.02% Debt Debt-to-Equity RatioN/A Current Ratio5.58 Quick Ratio5.43 Sales & Book Value Annual Sales$77.43 million Price / Sales33.65 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book15.10Miscellaneous Outstanding Shares60,140,000Free Float57,313,000Market Cap$2.61 billion OptionableOptionable Beta1.90 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. David P. Meeker M.D. (Age 70)Chairman, President & CEO Comp: $1.17MMr. Hunter C. Smith M.B.A. (Age 55)CFO & Treasurer Comp: $692.2kMr. Joseph Shulman (Age 49)Chief Technical Officer Comp: $608.2kMr. Yann Mazabraud (Age 51)Executive VP & Head of International Comp: $747.43kMs. Jennifer Lee (Age 48)Executive VP & Head of North America Comp: $644.2kMr. Christopher German (Age 53)Corporate Controller, Principal Accounting Officer & Executive Director Mr. David ConnollyHead of Investor Relations & Corporate CommunicationsMr. Jim FlahertySenior VP & General CounselMs. Sarah RyanVice President of Sales & MarketingMs. Pamela J. Cramer (Age 50)Chief Human Resources Officer More ExecutivesKey CompetitorsKeros TherapeuticsNASDAQ:KROSTG TherapeuticsNASDAQ:TGTXRocket PharmaceuticalsNASDAQ:RCKTAlpine Immune SciencesNASDAQ:ALPNDyne TherapeuticsNASDAQ:DYNView All CompetitorsInsiders & InstitutionsHealthcare of Ontario Pension Plan Trust FundSold 25,157 shares on 3/21/2024Ownership: 0.252%Joseph ShulmanSold 18,235 sharesTotal: $735,599.90 ($40.34/share)David P MeekerSold 45,494 sharesTotal: $1.78 M ($39.22/share)Hunter C SmithSold 15,515 sharesTotal: $608,498.30 ($39.22/share)Yann MazabraudSold 16,000 sharesTotal: $627,520.00 ($39.22/share)View All Insider TransactionsView All Institutional Transactions RYTM Stock Analysis - Frequently Asked Questions Should I buy or sell Rhythm Pharmaceuticals stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RYTM shares. View RYTM analyst ratings or view top-rated stocks. What is Rhythm Pharmaceuticals' stock price target for 2024? 5 Wall Street analysts have issued 1 year target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price targets range from $27.00 to $55.00. On average, they expect the company's stock price to reach $47.40 in the next year. This suggests a possible upside of 9.4% from the stock's current price. View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts. How have RYTM shares performed in 2024? Rhythm Pharmaceuticals' stock was trading at $45.97 on January 1st, 2024. Since then, RYTM stock has decreased by 5.7% and is now trading at $43.33. View the best growth stocks for 2024 here. When is Rhythm Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our RYTM earnings forecast. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) released its earnings results on Thursday, February, 22nd. The company reported ($0.70) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.70). The company earned $24.23 million during the quarter, compared to analyst estimates of $25.38 million. Rhythm Pharmaceuticals had a negative trailing twelve-month return on equity of 96.02% and a negative net margin of 238.50%. The company's revenue for the quarter was up 175.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.75) EPS. What ETFs hold Rhythm Pharmaceuticals' stock? ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).BlackRock Future Health ETF (BMED). What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT). When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (13.63%), Goldman Sachs Group Inc. (8.54%), Vanguard Group Inc. (5.46%), Vanguard Group Inc. (5.37%), Federated Hermes Inc. (3.91%) and Perceptive Advisors LLC (3.64%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, William T Roberts and Yann Mazabraud. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RYTM) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.